Next-12-month backlog conversion is the portion of contracted R&D Solutions backlog that IQVIA expects to recognize as revenue over the following twelve months.
At June 30, 2026, IQVIA expected approximately $9.2B of backlog to convert to revenue in the next twelve months, up 7.5% year over year. Total R&D Solutions contracted backlog was $34.2B.
Timing visibility, not guaranteed revenue
The $9.2B figure is management's expected conversion of existing contracts, not a promise that every dollar will be recognized on schedule. Trial timing, scope changes, cancellations, foreign exchange, reimbursed expenses, and client decisions can move actual revenue.
Use it with net new bookings to distinguish replenishment of future work from conversion of work already contracted.
Primary sources: IQVIA Q2 2026 Form 10-Q and Q2 2026 earnings release filed with the SEC.
Continue Research
Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.
Compare stocks
Compare near-term revenue visibility from contracted clinical-research backlog rather than total backlog alone.
Explore more topics in the Financial Research Encyclopedia.